Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2026 Earnings Call Transcript
Operator: Please standby, your meeting is about to begin. Hello and welcome everyone joining today's Neurocrine Biosciences, Inc. Q1 2026 Earnings Call.
Neurocrine Biosciences Inc (NBIX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 122,226 | $16,102,051 | +9% | 0.01% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 3,046 | $401,280 | -94% | 0% |
| 3. | 2,500 | $329,350 | 0% | ||
| 4. | Bayforest Capital Theodoros Tsagaris | 981 | $129,237 | -51% | 0.14% |
| 5. | Aubrey Capital Management Andrew Dalrymple And Barry Mccorkell | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.96 | 22,300 | $132,796.50 | 3,527,700 | 2011-10-12 | Filing | |
| $5.96 | 1,000 | $5,955.00 | 757,600 | 2011-10-12 | Filing | |
| $5.96 | 6,200 | $36,921.00 | 1,236,665 | 2011-10-12 | Filing | |
| $5.73 | 3,800 | $21,768.30 | 3,505,400 | 2011-10-11 | Filing | |
| $5.59 | 44,700 | $249,779.13 | 3,501,600 | 2011-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $132.71 | 1,812 | $240,478.31 | 140,407 | 2026-01-16 | Filing | |
| $132.70 | 34,588 | $4,589,979.79 | 140,407 | 2026-01-16 | Filing | |
| $155.09 | 1,190 | $184,558.41 | 6,239 | 2025-12-16 | Filing | |
| $152.23 | 5,000 | $761,143.50 | 7,429 | 2025-12-15 | Filing | |
| $159.65 | 4,376 | $698,615.27 | 43,405 | 2025-12-08 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,726,344 | $622,648,559 | 0.03% | |
| 2. | 4,511,904 | $594,398,233 | 0.01% | |
| 3. | 1,221,036 | $160,859,283 | 0.02% | |
| 4. | 711,762 | $93,753,135 | 0.02% | |
| 5. | 702,492 | $92,546,232 | 0.02% |
News See All
Neurocrine Biosciences (NBIX) Announces First Presentation of New Two-Year Data From Phase 3 CAHtalyst® Adult Study
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy according to analysts. On April 22, Neurocrine Biosciences, Inc.
9 Best Drug Stocks to Buy According to Analysts
On April 27, Jurrien Timmer, director of global macro at Fidelity Investments, appeared on CNBC to talk about the market and oil prices, and how necessary it is for oil prices to retreat from their highs...
Truist Lowers Neurocrine Biosciences, Inc.'s (NBIX) PT Following 2026 Outlook Update
TheFly reported on February 17 that Truist reduced its price target on NBIX to $140 from $169 and maintained a Buy rating on the stock. The increase came after management's 2026 projection, and...
7 Oversold Pharma Stocks to Buy Now
In 2024, the pharmaceutical sector in the United States was valued at $634.32 billion, and by 2030, it is expected to have grown to $883.97 billion.
Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza
TheFly reported on February 12 that Needham lowered its price target on NBIX to $185 from $187 and maintained a Buy rating. The company is still hopeful about Crenessity's growth in 2026 and anticipates...
7 Most Promising Psychedelic Stocks According to Hedge Funds
The psychedelic industry is poised to have a significant "second wave," transforming from a speculative, counterculture-driven movement into a recognized cornerstone of the US healthcare system.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript February 11, 2026Neurocrine Biosciences, Inc. misses on earnings expectations.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to today's Neurocrine Biosciences Third Quarter 2025 Results Call. [Operator Instructions] Please note, this call is being recorded.
Should You be Optimistic on Neurocrine Biosciences (NBIX)?
PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center